MUMSS
BIO icon

Mitsubishi UFJ Morgan Stanley Securities’s Bio-Rad Laboratories Class A BIO Stock Holding History

Mitsubishi UFJ Morgan Stanley Securities’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-90
Closed -$58K – 105
2021
Q2 		$58K Buy
+90
New +$54.8K 0.43% 52

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Mitsubishi UFJ Morgan Stanley Securities's BIO Position: Q3 2021 in Review

Mitsubishi UFJ Morgan Stanley Securities sold out of Bio-Rad Laboratories Class A (BIO) in Q3 2021, closing a stake of 90 shares — an estimated $58K sold.

Mitsubishi UFJ Morgan Stanley Securities first reported a position in BIO in Q2 2021 and held it in 1 quarter. The position peaked at $58K in Q2 2021. 507 funds tracked by Wall St. Rank hold BIO as of Q3 2021.

  • Mitsubishi UFJ Morgan Stanley Securities reported no remaining Bio-Rad Laboratories Class A position as of Q3 2021 after selling out during the quarter.
  • Mitsubishi UFJ Morgan Stanley Securities sold 90 Bio-Rad Laboratories Class A shares in Q3 2021, an estimated $58K.
  • Mitsubishi UFJ Morgan Stanley Securities first reported a position in Bio-Rad Laboratories Class A in Q2 2021 and held it in 1 quarter.
  • Mitsubishi UFJ Morgan Stanley Securities's Bio-Rad Laboratories Class A position peaked at $58K in Q2 2021.
  • 507 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2021.

Based on Mitsubishi UFJ Morgan Stanley Securities's 13F filing for Q3 2021, filed 12 Nov 2021.